Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F12%3A00058445" target="_blank" >RIV/00023001:_____/12:00058445 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.nel.edu/home.htm" target="_blank" >http://www.nel.edu/home.htm</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy

Popis výsledku v původním jazyce

OBJECTIVES: A significant inter-individual variability in statin treatment efficacy is likely to have a strong genetic background. A candidate gene with the potential to influence statin treatment efficacy is SLCO1B1. This gene codes for the solute carrier organic anion transporter, which has been shown to regulate the hepatic uptake of statins and some other drugs. MATERIALS AND METHODS: The SLCO1B1 rs4149056 (T>C) polymorphism was successfully analysed in a group of 253 patients with dyslipidemia (treated with simvastin or atorvastatin, 10 or 20 mg per day) and 470 healthy normolipidemic controls. The polymorphism was analysed using nested PCR-RFLP. Lipid levels (total, LDL and HDL cholesterol; triglycerides) were analysed before and after 10-13 weeks of treatment. RESULTS: After treatment, as expected, there was a significant decrease both in the total cholesterol (7.60+-1.36 -> 5.37+-1.12 mmol/L, p<0.001) and LDL cholesterol (5.04+-1.34 -> 3.17+-0.99 mmol/L, p<0.001) levels. The di

Název v anglickém jazyce

Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy

Popis výsledku anglicky

OBJECTIVES: A significant inter-individual variability in statin treatment efficacy is likely to have a strong genetic background. A candidate gene with the potential to influence statin treatment efficacy is SLCO1B1. This gene codes for the solute carrier organic anion transporter, which has been shown to regulate the hepatic uptake of statins and some other drugs. MATERIALS AND METHODS: The SLCO1B1 rs4149056 (T>C) polymorphism was successfully analysed in a group of 253 patients with dyslipidemia (treated with simvastin or atorvastatin, 10 or 20 mg per day) and 470 healthy normolipidemic controls. The polymorphism was analysed using nested PCR-RFLP. Lipid levels (total, LDL and HDL cholesterol; triglycerides) were analysed before and after 10-13 weeks of treatment. RESULTS: After treatment, as expected, there was a significant decrease both in the total cholesterol (7.60+-1.36 -> 5.37+-1.12 mmol/L, p<0.001) and LDL cholesterol (5.04+-1.34 -> 3.17+-0.99 mmol/L, p<0.001) levels. The di

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT11307" target="_blank" >NT11307: Analýza genetické predisposice k nežádoucím účinkům hypolipidemické léčby</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neuroendocrinology letters

ISSN

0172-780X

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

suppl. 2

Stát vydavatele periodika

SE - Švédské království

Počet stran výsledku

4

Strana od-do

22-25

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—